Serviços Personalizados
Journal
Artigo
Indicadores
Citado por SciELO
Links relacionados
Similares em SciELO
Compartilhar
Anales de la Facultad de Ciencias Médicas (Asunción)
versão impressa ISSN 1816-8949
Resumo
RICO FONTALVO, Jorge e VAZQUEZ JIMENEZ, Lourdes. Diabetic kidney disease: pillars in treatment. An. Fac. Cienc. Méd. (Asunción) [online]. 2023, vol.56, n.1, pp.133-136. ISSN 1816-8949. https://doi.org/10.18004/anales/2023.056.01.133.
Introduction:
Diabetes mellitus (DM) is a very common chronic inflammatory disease and finally one of the fastest-growing global health emergencies in recent decades. Three axes impact the progression of renal compromise in diabetic patients. The hemodynamic, metabolic, and inflammatory axis. We highlight the importance of the inflammatory component as a leading actor in developing Diabetic Kidney Disease (DKD). The management of the patient with CKD must be holistic, with three clear objectives: reasonable metabolic control, slowing the progression of kidney disease, and reducing adverse cardiovascular outcomes. Currently, in addition to non-pharmacological interventions, the control of risk factors, and the use of ACE inhibitors/ARA II, there are new pillars in the treatment of CKD.
Objectives:
The objective of this communication is to review the new pillars in the management of DKD. In the bibliographic review that was carried out, we found that there are three new pillars in the treatment. SGLT-2 inhibitors, GLP-1 receptor agonists, and finally finerenone, which is a selective non-steroidal antagonist of the mineralocorticoid receptor (MRA), not an antidiabetic. With these new therapies, the current management of these patients has changed considerably.
Conclusion:
There are new pillars in the treatment of DKD. The SGLT-2 inhibitors, the GLP-1 receptor agonists, and the use of MRAs such as finerenone provide us with cardio-renal benefits and which today make the treatment of CKD have a better outlook.
Palavras-chave : Diabetic kidney disease; Diabetes Mellitus; iSGLT-2; receptor agonists GLP-1 finerenone..